

Leqembi (lecanemab-irmb)



METRO INFUSION CENTER

REFERRAL STATUS: ☐ New Referral ☐ Dose or Frequency Change ☐ Order Renewal

Infusion Office Preference: _____

PATIENT INFORMATION			
Date:		Patient Name:	
DOB:			
<input type="checkbox"/> NKDA Allergies:		Weight (lbs / kg):	
Height:			
Patient Status: <input type="checkbox"/> New to Therapy <input type="checkbox"/> Continuing Therapy - Last Treatment Date:		Next Due Date:	
DIAGNOSIS AND ICD 10 CODE			
<input type="checkbox"/> Alzheimer's disease with early onset		ICD 10 Code: G30.0	
<input type="checkbox"/> Mild Cognitive Impairment, So stated		ICD 10 Code: G31.84	
<input type="checkbox"/> other ICD10 Code:)		Description:	
G30.X CODES BELOW REQUIRE SECONDARY F02.8x DIAGNOSIS CODE- PLEASE SELECT ONE FROM EACH COLUMN			
		<u>Secondary</u>	
<input type="checkbox"/> G30.1 Alzheimer's disease late onset		<input type="checkbox"/> F02.80 Dementia without behavioral disturbance	
<input type="checkbox"/> G30.8 Other Alzheimer's disease		<input type="checkbox"/> F02.81 Dementia with behavioral disturbance	
<input type="checkbox"/> G30.9 Alzheimer's disease , unspecified			
REQUIRED DOCUMENTATION			
<input type="checkbox"/> This signed order form by the provider <input type="checkbox"/> Patient demographics AND insurance info <input type="checkbox"/> Clinical/Progress notes			
Prescriber must indicate that the following requirements have been met (provide supporting documentation)			
<input type="checkbox"/> Beta Amyloid Pathology Confirmed via:			
↳ <input type="checkbox"/> Amyloid PET Scan OR <input type="checkbox"/> CFS Analysis-Date: _____ Result: _____			
<input type="checkbox"/> Cognitive Assessment Used: _____ Date: _____ Result: _____			
<input type="checkbox"/> ApoE εε4 Genetic Test - Date: _____ Result: <input type="checkbox"/> Homozygote <input type="checkbox"/> Heterozygote <input type="checkbox"/> Noncarrier			
MEDICARE REGISTRATION # IF APPLICABLE _____			
MEDICATION ORDERS(Note: Only one stage of treatment may be ordered at a time)			
<input type="checkbox"/> Stage 1 (Infusions #1-4) ✓ Leqembi 10mg/kg IV every two weeks x 4 doses. Each infusion to be given over one hour. Required Documentation to Initiate this Phase: <input type="checkbox"/> MRI of brain within one year prior to first infusion. Date of MRI: o By checking this box, I confirm that Beta Amyloid Pathology has been confirmed via CSF or PET.	<input type="checkbox"/> Stage 2 (Infusions #5 and #6) ✓ Leqembi 10mg/kg IV every two weeks x 2 doses. Each infusion to be given over one hour. Required Documentation to Initiate this Phase: <input type="checkbox"/> By checking this box, I confirm that patient has undergone MRI of brain before dose #5. I have reviewed the results and clear patient to proceed with infusions #5 and #6.	<input type="checkbox"/> Stage 3 (Infusions #7-13) ✓ Leqembi 10mg/kg IV every two weeks x 7 doses. Each infusion to be given over one hour. Required Documentation to Initiate this Phase: <input type="checkbox"/> By checking this box, I confirm that patient has undergone MRI of brain before dose #7. I have reviewed the results and clear patient to proceed with infusions #7 through #13.	* Stage 4 (Infusions #14 & beyond) <input type="checkbox"/> Leqembi 10mg/kg IV every two weeks over one hour. OR <input type="checkbox"/> Leqembi 10mg/kg IV every four weeks over one hour. Required Documentation to Initiate this Phase: <input type="checkbox"/> By checking this box, I confirm that patient has undergone MRI of brain before dose #14. I have reviewed the results and clear patient to proceed with infusions #14 and beyond as ordered above

PRE-INFUSION : <input checked="" type="checkbox"/> Confirm baseline MRI results prior to initiation of treatment <input checked="" type="checkbox"/> Confirm MRI completed and reviewed by prescriber prior to the 5 th , 7 th , and 14 th treatment <input checked="" type="checkbox"/> Measure and record weight prior to each treatment to determine dose <input checked="" type="checkbox"/> Hold infusion and notify provider if patient reports: <ul style="list-style-type: none"> • Headache • Dizziness • Nausea • Vision Changes • New or worsening confusion 	Post -INFUSION : <input checked="" type="checkbox"/> Educate patient/care partner to report headache, dizziness, nausea, vision changes, or new/worsening confusion. <input checked="" type="checkbox"/> Fax infusion record to provider below :
--	---

PRESCRIBER INFORMATION		
Provider Name (print)	Provider Signature**:	Date:
Office Phone	Office Fax	

***Amyloid Related Imaging Abnormalities (ARIA): Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment with LEQEMBI. Referring physician to monitor patient*

Fax referral to 866-507-1164 or email to bionurses@metroinfusioncenter.com

All information contained in this order form is strictly confidential and will become 01/29/25 part of the patient's medical record.

Page 2 of 2

Created 01/29/25